Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340697 · ClinicalTrials.gov registry record · Phase 1
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
A Phase 1 study of Actinic Keratosis (AK), sponsored by Rubedo Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT07340697: Recruiting Phase 1 study of Actinic Keratosis (AK), sponsored by Rubedo Life Sciences.
NCT07340697 is a Phase 1 study of Actinic Keratosis (AK) that is actively recruiting participants, run by Rubedo Life Sciences. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07340697, a Phase 1 study of Actinic Keratosis (AK), is actively recruiting participants, sponsored by Rubedo Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatment with RLS-1496 cream is to clear or decrease the number of AK in the treated area, per lesion counts performed by the Investigator. The main questions it aims to answer are: * Is it safe to apply topical RLS-1496 cream to treat AK once daily for 28 days? * Does topical RLS-1496 lower the number of AKs or eliminate AKs in a treated area when applied once daily for 28 days? Researchers will compare results on the left (treated with RLS-1496) and right (no treatment) forearm. Participants will apply RLS-1496 to an identified area on the left forearm once each day for 28 days and have intermittent clinic visits to examine the arms and have the AK lesions counted until 28 days after the last application of RLS-1496. Participants will also have small skin biopsies on the arms.
Primary Outcome
Treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG RLS-1496 1.0% cream
Study Locations (4)
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Minnesota
- Minnesota Clinical Study Center - New Brighton
Nebraska
- Schlessinger MD Skin Research Center - Omaha
Texas
- Austin Institute for Clinical Research - Pflugerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT07340697 shows while recruiting
NCT07340697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Actinic Keratosis (AK) appearing as the primary indexed condition, and to 1 intervention - of which RLS-1496 1.0% cream is the first listed.
NCT07340697 reports a single indexed study location in Arkansas, Minnesota, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07340697 about?
NCT07340697 is a clinical study titled "Evaluate RLS-1496 Topical Cream for Actinic Keratosis". This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatmen...
What is the current status of trial NCT07340697?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01. Estimated completion is 2026-05.
What conditions does trial NCT07340697 study?
This clinical trial studies the following conditions: Actinic Keratosis (AK).
What interventions are being tested in trial NCT07340697?
The interventions under investigation include: RLS-1496 1.0% cream (DRUG).
Who is sponsoring clinical trial NCT07340697?
This trial is sponsored by Rubedo Life Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07340697 being conducted?
This trial has 4 study locations across Arkansas, Minnesota, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis (AK)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07340697's enrollment target sits among peer trials
24 1521st of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia